CAJ | 학술논문

目的：探讨加用阿立哌唑对利培酮所致高催乳素血症的中老年女性慢性精神分裂症患者的维持期病情稳定性及安全性。方法采用随机数表法将107例长期服用利培酮维持治疗的病情稳定的、有血清催乳素不同程度升高的中老年（年龄≥50岁）、符合《中国精神障碍分类与诊断标准（第3版）》（CCMD -3）精神分裂症诊断标准的女性患者分为研究组（52例）和对照组（55例）。研究组减1mg 利培酮的同时加用阿立哌唑5mg/ d，对照组维持原有治疗方案不变，总疗程12周，于治疗前和治疗第4、8、12周末检测血清催乳素含量，并采用阳性和阴性症状量表（PANSS）、副反应量表（TESS）评定症状和不良反应。结果研究组治疗第4、8、12周末血清催乳素水平较同期对照组低，差异有统计学意义（P <0.01）。两组治疗前后 PANSS 及 TESS 评分差异均无统计学意义（P >0.05）。结论利培酮联合小剂量阿立哌唑可维持中老年女性精神分裂症患者的病情稳定，且有助于降低利培酮所致血清高催乳素水平，药物不良反应未见增多。
목적：탐토가용아립고서대리배동소치고최유소혈증적중노년녀성만성정신분렬증환자적유지기병정은정성급안전성。방법채용수궤수표법장107례장기복용리배동유지치료적병정은정적、유혈청최유소불동정도승고적중노년（년령≥50세）、부합《중국정신장애분류여진단표준（제3판）》（CCMD -3）정신분렬증진단표준적녀성환자분위연구조（52례）화대조조（55례）。연구조감1mg 리배동적동시가용아립고서5mg/ d，대조조유지원유치료방안불변，총료정12주，우치료전화치료제4、8、12주말검측혈청최유소함량，병채용양성화음성증상량표（PANSS）、부반응량표（TESS）평정증상화불량반응。결과연구조치료제4、8、12주말혈청최유소수평교동기대조조저，차이유통계학의의（P <0.01）。량조치료전후 PANSS 급 TESS 평분차이균무통계학의의（P >0.05）。결론리배동연합소제량아립고서가유지중노년녀성정신분렬증환자적병정은정，차유조우강저리배동소치혈청고최유소수평，약물불량반응미견증다。
Objective To investigate the efficacy and safety of aripiprazole on the hyperprolactinmia induced by risperidone in maintenance period patients with amenorrhea female schizophrenia. Methods 107 maintenance period patients with amenorrhea female and hyperprolactinmia schizophrenia(standard of CCMD - 3)patients who had received risperidone were randomly by random number table assigned to research group(n = 52)and control group(n = 55). And then the research group were administered additional aripi-prazole 5 mg daily when reduce 1mg risperidone and the control group patients were no - changed in the dosage of risperidone for 12 weeks. The plasma prolactin leveI was measured before and after treatment of 4th ,8th ,12th week,and the Positive and Negative Syn-drome Scale(PANSS)and Treatment Emergent Symptom Scale(TESS)were assessed. Results The plasma levels of reseach group at 4th ,8th ,12th were lower than that of the control group. The incidence of side effects and the Positive and Negative Syndrome Scale (PANSS)showed no significant difference between the two groups(P > 0. 05). Conclusion The results indicate that aripiprazole combined with risperidone may be effective and safe for the treatment of maintenance period patients with amenorrhea female and hyper-prolactinmia patients with risperidone induced hyperprolactinemia.